Abstract

Although Plasmodium vivax is a leading cause of malaria around the world, only a handful of vivax antigens are being studied for vaccine development. Here, we investigated genetic signatures of selection and geospatial genetic diversity of two leading vivax vaccine antigens – Plasmodium vivax merozoite surface protein 1 (pvmsp-1) and Plasmodium vivax circumsporozoite protein (pvcsp). Using scalable next-generation sequencing, we deep-sequenced amplicons of the 42 kDa region of pvmsp-1 (n = 44) and the complete gene of pvcsp (n = 47) from Cambodian isolates. These sequences were then compared with global parasite populations obtained from GenBank. Using a combination of statistical and phylogenetic methods to assess for selection and population structure, we found strong evidence of balancing selection in the 42 kDa region of pvmsp-1, which varied significantly over the length of the gene, consistent with immune-mediated selection. In pvcsp, the highly variable central repeat region also showed patterns consistent with immune selection, which were lacking outside the repeat. The patterns of selection seen in both genes differed from their P. falciparum orthologs. In addition, we found that, similar to merozoite antigens from P. falciparum malaria, genetic diversity of pvmsp-1 sequences showed no geographic clustering, while the non-merozoite antigen, pvcsp, showed strong geographic clustering. These findings suggest that while immune selection may act on both vivax vaccine candidate antigens, the geographic distribution of genetic variability differs greatly between these two genes. The selective forces driving this diversification could lead to antigen escape and vaccine failure. Better understanding the geographic distribution of genetic variability in vaccine candidate antigens will be key to designing and implementing efficacious vaccines.

Highlights

  • Plasmodium vivax causes 80 to 300 million infections per year and over 2.5 billion people remain at risk of infection despite malaria elimination efforts [1]

  • The fact that humans naturally develop partial immunity to P. vivax and P. falciparum lends hope for effective vaccines against these parasites; because the majority of global malaria research funding targets P. falciparum [6,7], only a handful of P. vivax antigens are currently being considered for vaccine development [8]

  • Some vaccines against P. vivax are being developed, little is known about the geospatial genetic diversity and selective constraints of the parasite surface antigens that these vaccines target

Read more

Summary

Introduction

Plasmodium vivax causes 80 to 300 million infections per year and over 2.5 billion people remain at risk of infection despite malaria elimination efforts [1]. The fact that humans naturally develop partial immunity to P. vivax and P. falciparum lends hope for effective vaccines against these parasites; because the majority of global malaria research funding targets P. falciparum [6,7], only a handful of P. vivax antigens are currently being considered for vaccine development [8]. Among these are P. vivax merozoite surface protein 1 (pvmsp-1) and circumsporozoite protein (pvcsp).

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call